Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

20.62 +0.07 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144,489
Open 20.43
Bid (Size) 20.00 (1)
Ask (Size) 23.81 (1)
Prev. Close 20.55
Today's Range 20.23 - 20.98
52wk Range 7.750 - 27.17
Shares Outstanding 52,121,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+20.2%
+20.2%
1 Month
-20.0%
-20.0%
3 Month
+20.7%
+20.7%
6 Month
+83.1%
+83.1%
1 Year
+12.4%
+12.4%

More News

Read More
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
From Assembly Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
From Assembly Biosciences, Inc.
Via GlobeNewswire
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
From Assembly Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
Via Benzinga
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Assembly Biosciences, Inc. - Common Stock publicly traded?
Yes, Assembly Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Assembly Biosciences, Inc. - Common Stock trade on?
Assembly Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Assembly Biosciences, Inc. - Common Stock?
The ticker symbol for Assembly Biosciences, Inc. - Common Stock is ASMB on the Nasdaq Stock Market
What is the current price of Assembly Biosciences, Inc. - Common Stock?
The current price of Assembly Biosciences, Inc. - Common Stock is 20.62
When was Assembly Biosciences, Inc. - Common Stock last traded?
The last trade of Assembly Biosciences, Inc. - Common Stock was at 09/17/25 04:00 PM ET
What is the market capitalization of Assembly Biosciences, Inc. - Common Stock?
The market capitalization of Assembly Biosciences, Inc. - Common Stock is 1.07B
How many shares of Assembly Biosciences, Inc. - Common Stock are outstanding?
Assembly Biosciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.